[1]
Garriga M,Solé E,González-Pinto A,Selva-Vera G,Arranz B,Amann BL,Saiz-Ruiz J,Pérez-Blanco J,Vieta E, Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2017 Oct
[PubMed PMID: 28882405]
Level 3 (low-level) evidence
[2]
Suttajit S, Srisurapanont M, Maneeton N, Maneeton B. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug design, development and therapy. 2014:8():827-38. doi: 10.2147/DDDT.S63779. Epub 2014 Jun 25
[PubMed PMID: 25028535]
Level 1 (high-level) evidence
[3]
Lindström L,Lindström E,Nilsson M,Höistad M, Maintenance therapy with second generation antipsychotics for bipolar disorder - A systematic review and meta-analysis. Journal of affective disorders. 2017 Apr 15;
[PubMed PMID: 28222360]
Level 1 (high-level) evidence
[4]
Maneeton N, Maneeton B, Woottiluk P, Likhitsathian S, Suttajit S, Boonyanaruthee V, Srisurapanont M. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug design, development and therapy. 2016:10():259-76. doi: 10.2147/DDDT.S89485. Epub 2016 Jan 12
[PubMed PMID: 26834458]
Level 1 (high-level) evidence
[5]
Villarreal G, Hamner MB, Cañive JM, Robert S, Calais LA, Durklaski V, Zhai Y, Qualls C. Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. The American journal of psychiatry. 2016 Dec 1:173(12):1205-1212
[PubMed PMID: 27418378]
Level 1 (high-level) evidence
[6]
Yuan M, Sperry L, Malhado-Chang N, Duffy A, Wheelock V, Farias S, O'Connor K, Olichney J, Shahlaie K, Zhang L. Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study. Brain and behavior. 2017 Jun:7(6):e00639. doi: 10.1002/brb3.639. Epub 2017 Apr 14
[PubMed PMID: 28638698]
Level 2 (mid-level) evidence
[7]
Nagata T, Nakajima S, Shinagawa S, Plitman E, Nakayama K, Graff-Guerrero A, Mimura M. Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer's Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study. Journal of Alzheimer's disease : JAD. 2017:60(1):263-272. doi: 10.3233/JAD-170412. Epub
[PubMed PMID: 28800334]
[8]
Riedel M, Schmitz M, Østergaard PK, Ferrannini L, Franco MA, Alfano V, Vansvik ED. Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: a randomised, double-blind, crossover study (eXtRa). Schizophrenia research. 2015 Mar:162(1-3):162-8. doi: 10.1016/j.schres.2014.12.027. Epub 2015 Jan 12
[PubMed PMID: 25592805]
Level 1 (high-level) evidence
[9]
Weber SR, Wehr AM, Duchemin AM. Prevalence of antipsychotic prescriptions among patients with anxiety disorders treated in inpatient and outpatient psychiatric settings. Journal of affective disorders. 2016 Feb:191():292-9. doi: 10.1016/j.jad.2015.11.031. Epub 2015 Nov 26
[PubMed PMID: 26688499]
[10]
Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology. 1993:112(2-3):285-92
[PubMed PMID: 7871032]
[11]
Cross AJ, Widzowski D, Maciag C, Zacco A, Hudzik T, Liu J, Nyberg S, Wood MW. Quetiapine and its metabolite norquetiapine: translation from in vitro pharmacology to in vivo efficacy in rodent models. British journal of pharmacology. 2016 Jan:173(1):155-66. doi: 10.1111/bph.13346. Epub 2015 Dec 1
[PubMed PMID: 26436896]
[12]
Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2008 Sep:33(10):2303-12
[PubMed PMID: 18059438]
[13]
Figueroa C, Brecher M, Hamer-Maansson JE, Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Progress in neuro-psychopharmacology & biological psychiatry. 2009 Mar 17:33(2):199-204. doi: 10.1016/j.pnpbp.2008.09.026. Epub 2008 Oct 9
[PubMed PMID: 18948162]
[14]
Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A. Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Critical care (London, England). 2012 Jul 26:16(4):R136. doi: 10.1186/cc11441. Epub 2012 Jul 26
[PubMed PMID: 22835221]
[15]
DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clinical pharmacokinetics. 2001:40(7):509-22
[PubMed PMID: 11510628]
[16]
Bergman H, Walker DM, Nikolakopoulou A, Soares-Weiser K, Adams CE. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health technology assessment (Winchester, England). 2017 Aug:21(43):1-218. doi: 10.3310/hta21430. Epub
[PubMed PMID: 28812541]
Level 1 (high-level) evidence
[17]
Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV, Correll CU, Carvalho AF. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Therapeutics and clinical risk management. 2017:13():757-777. doi: 10.2147/TCRM.S117321. Epub 2017 Jun 29
[PubMed PMID: 28721057]
[18]
Aronow WS,Shamliyan TA, Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders. Annals of translational medicine. 2018 Apr
[PubMed PMID: 29862236]
[19]
Jain V, Patel RK, Kapadia Z, Galiveeti S, Banerji M, Hope L. Drugs and hyperglycemia: A practical guide. Maturitas. 2017 Oct:104():80-83. doi: 10.1016/j.maturitas.2017.08.006. Epub 2017 Aug 12
[PubMed PMID: 28923179]
[20]
Levine M, Ruha AM. Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management. CNS drugs. 2012 Jul 1:26(7):601-11. doi: 10.2165/11631640-000000000-00000. Epub
[PubMed PMID: 22668123]
[21]
Minns AB,Clark RF, Toxicology and overdose of atypical antipsychotics. The Journal of emergency medicine. 2012 Nov
[PubMed PMID: 22555052]
[22]
Arslan ED, Demir A, Yilmaz F, Kavalci C, Karakilic E, Çelikel E. Treatment of quetiapine overdose with intravenous lipid emulsion. The Keio journal of medicine. 2013:62(2):53-7
[PubMed PMID: 23708294]
[23]
Erythema nodosum associated with pregnancy. Case reports., Langer R,Bukovsky I,Lipshitz I,Ariely S,Caspi E,, European journal of obstetrics, gynecology, and reproductive biology, 1979 Dec
[PubMed PMID: 23768031]
Level 3 (low-level) evidence
[24]
Cole JB,Stellpflug SJ,Ellsworth H,Harris CR, Reversal of quetiapine-induced altered mental status with physostigmine: a case series. The American journal of emergency medicine. 2012 Jul;
[PubMed PMID: 21802878]
Level 2 (mid-level) evidence